€300M
The pre-IPO financing comes from a cornerstone investor to support affordable mRNA vaccine development and modular manufacturing.
N
Normax
Normax develops and manufactures accessible mRNA vaccines and modular production facilities.
Ireland
€300MTotal raised
Normax is an Irish biotechnology firm focused on developing and manufacturing affordable mRNA vaccines to combat infectious diseases.
Team
PJ
Peter Jensen
CEO and Chairman